Hydroxystilbene compounds for reducing/inhibiting protein glycation

Abstract

The hydroxystilbenes are well suited for reducing or inhibiting the glycation of certain substrates, for example the proteins of human skin and/or nails and/or hair, advantageously to preventatively and/or curatively combat glycation-related aging of the skin/nails/hair.

What is claimed is:  
     
         1 . A regime and/or regimen for reducing or inhibiting the glycation of susceptible substrates of an individual subject in need of such treatment, comprising administering to such subject an effective amount of at least one hydroxystilbene compound, for such period of time as required to elicit reduction or inhibition of the glycation of the susceptible substrates, said period of time being at least 3 to 8 weeks.  
     
     
         2 . A regime and/or regimen for reducing or inhibiting the glycation of proteins of an individual subject in need of such treatment, comprising administering to such subject an effective amount of at least one hydroxystilbene compound, for such period of time as required to elicit reduction or inhibition of the glycation of the proteins, said period of time being at least 3 to 8 weeks.  
     
     
         3 . A regime and/or regimen for reducing or inhibiting the glycation of susceptible proteins of the skin of an individual subject in need of such treatment, comprising topically administering to such subject an effective amount of at least one hydroxystilbene compound, for such period of time as required to elicit reduction or inhibition of the glycation of the susceptible proteins of the skin, said period of time being at least 3 to 8 weeks.  
     
     
         4 . The regime and/or regimen as defined by  claim 3 , for reducing or inhibiting the glycation of dermal proteins.  
     
     
         5 . The regime and/or regimen as defined by  claim 3 , for reducing or inhibiting the glycation of collagen.  
     
     
         6 . The regime and/or regimen as defined by  claim 3 , for treating aging of human skin.  
     
     
         7 . The regime and/or regimen as defined by  claim 1 , said at least one hydroxystilbene compound having the structural formula (I):  
       
         
           
           
               
               
           
         
       
       in which n is an integer ranging from 0 to 4 and m is an integer ranging from 0 to 5.  
     
     
         8 . The regime and/or regimen as defined by  claim 3 , said at least one hydroxystilbene compound having the structural formula (I):  
       
         
           
           
               
               
           
         
       
       in which n is an integer ranging from 0 to 4 and m is an integer ranging from 0 to 5.  
     
     
         9 . The regime and/or regimen as defined by  claim 3 , wherein said at least one hydroxystilbene compound is: 
 4′-hydroxystilbene,    2′,4′-dihydroxystilbene,    3′,4′-dihydroxystilbene,    4,4′-dihydroxystilbene,    2′,4′,4-trihydroxystilbene,    3′,4′,4-trihydroxystilbene,    2,4,4′-trihydroxystilbene,    3,4,4′-trihydroxystilbene,    3,4′,5-trihydroxystilbene,    2′,3,4-trihydroxystilbene,    2,3′,4-trihydroxystilbene,    2′,2,4′-trihydroxystilbene,    2,4,4′,5-tetrahydroxystilbene,    2′,3,4′,5-tetrahydroxystilbene,    2,2′,4,4′-tetrahydroxystilbene,    3,3′,4′,5-tetrahydroxystilbene,    2,3′,4,4′-tetrahydroxystilbene,    3,3′,4,4′-tetrahydroxystilbene,    3,3′,4′,5,5′-pentahydroxystilbene,    2,2′,4,4′,6-pentahydroxystilbene,    2,3′,4,4′,6-pentahydroxystilbene,    2,2′,4,4′,6,6′-hexahydroxystilbene, or combination thereof.    
     
     
         10 . The regime and/or regimen as defined by  claim 9 , wherein said at least one hydroxystilbene compound is 3,4′,5-trihydroxystilbene.  
     
     
         11 . A regime and/or regimen for reducing or inhibiting the glycation of susceptible substrates of an individual subject in need of such treatment, comprising administering to such subject an effective amount of at least one hydroxystilbene compound, for such period of time as required to elicit reduction or inhibition of the glycation of the susceptible substrates, said period of time being at least 3 to 8 weeks, with the proviso that when said regime and/or regimen is for treating signs of aging of the skin, said signs are those resulting from glycation of collagen in the dermis.  
     
     
         12 . A regime and/or regimen for reducing or inhdibiting the glycation of proteins of an individual subject in need of such treatment, comprising administering to such subject an effective amount of at least one hydroxystilbene compound, for such period of time as required to elicit reduction or inhibition of the glycation of the proteins, said period of time being at least 3 to 8 weeks, with the proviso that when said regime and/or regimen is for treating signs of aging of the skin, said signs are those resulting from glycation of collagen in the dermis.  
     
     
         13 . A regime and/or regimen for reducing or inhibiting the glycation of susceptible proteins of the skin of an individual subject in need of such treatment, comprising topically administering to such subject an effective amount of at least one hydroxystilbene compound, for such period of time as required to elicit reduction or inhibition of the glycation of the susceptible proteins of the skin, said period of time being at least 3 to 8 weeks, with the proviso that when said regime and/or regimen is for treating signs of aging of the skin, said signs are those resulting from glycation of collagen in the dermis.  
     
     
         14 . The regime and/or regimen as defined by  claim 13 , for reducing or inhibiting the glycation of dermal proteins.  
     
     
         15 . The regime and/or regimen as defined by  claim 13 , for reducing or inhibiting the glycation of collagen.  
     
     
         16 . The regime and/or regimen as defined by  claim 13 , for treating aging of human skin.  
     
     
         17 . The regime and/or regimen as defined by  claim 11 , said at least one hydroxystilbene compound having the structural formula (I):  
       
         
           
           
               
               
           
         
       
       in which n is an integer ranging from 0 to 4 and m is an integer ranging from 0 to 5.  
     
     
         18 . The regime and/or regimen as defined by  claim 13 , said at least one hydroxystilbene compound having the structural formula (I):  
       
         
           
           
               
               
           
         
       
       in which n is an integer ranging from 0 to 4 and m is an integer ranging from 0 to 5.  
     
     
         19 . The regime and/or regimen as defined by  claim 13 , wherein said at least one hydroxystilbene compound is: 
 4′-hydroxystilbene,    2′,4′-dihydroxystilbene,    3′,4′-dihydroxystilbene,    4,4′-dihydroxystilbene,    2′,4′,4-trihydroxystilbene,    3′,4′,4-trihydroxystilbene,    2,4,4′-trihydroxystilbene,    3,4,4′-trihydroxystilbene,    3,4′,5-trihydroxystilbene,    2′,3,4-trihydroxystilbene,    2,3′,4-trihydroxystilbene,    2′,2,4′-trihydroxystilbene,    2,4,4′,5-tetrahydroxystilbene,    2′,3,4′,5-tetrahydroxystilbene,    2,2′,4,4′-tetrahydroxystilbene,    3,3′,4′,5-tetrahydroxystilbene,    2,3′,4,4′-tetrahydroxystilbene,    3,3′,4,4′-tetrahydroxystilbene,    3,3′,4′,5,5′-pentahydroxystilbene,    2,2′,4,4′,6-pentahydroxystilbene,    2,3′,4,4′,6-pentahydroxystilbene,    2,2′,4,4′,6,6′-hexahydroxystilbene, or combination thereof.    
     
     
         20 . The regime and/or regimen as defined by  claim 19 , wherein said at least one hydroxystilbene compound is 3,4′,5-trihydroxystilbene.